ARK Invest's position in NRIX, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 2,772,073 | $43.2M | 2.19% | #17 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | ARKG | Buy | Added | 350,410 | $5.6M |
| 2026-10-13 | ARKG | Buy | Added | 37,113 | $821K |
| 2026-10-12 | ARKG | Buy | Added | 95,661 | $2.1M |
| 2026-10-09 | ARKG | Buy | Added | 56,096 | $1.3M |
| 2026-10-08 | ARKG | Buy | Added | 157,387 | $3.5M |
| 2026-10-07 | ARKG | Buy | Added | 154,413 | $3.5M |
| 2026-10-06 | ARKG | Buy | Added | 21,477 | $485K |
| 2026-03-05 | ARKG | Buy | Added | 43,472 | $662K |
| 2026-03-04 | ARKG | Buy | Added | 17,347 | $282K |
| 2026-03-03 | ARKG | Buy | Added | 84,708 | $1.3M |
| 2025-12-11 | ARKG | Buy | Added | 26,928 | $514K |
| 2025-12-10 | ARKG | Buy | Added | 11,342 | $222K |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and…
See NRIX's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open NRIX on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.